中外製薬（4519） – Supplementary Materials for Consolidated Financial Results for Fiscal Year 2021.12(IFRS)

Supplementary Materials forConsolidated Financial Results forFiscal Year 2021. 12 (IFRS)Chugai Pharmaceutical co., ltd.Notes: 1.Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available atthe time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.3.Exchange rates used for each period are as follows.QTRCHFEURUSDSGDYTD*Market average exchange rateActual*FY20191-12Full-yearCHFEURUSDSGD109.72122.08109.0579.94*Market average exchange ratePeriod-endActualFY201931 Dec.112.31121.93108.8880.72CHFEURUSDSGD1-3QTR112.61120.19109.0278.724-6QTR111.54118.35107.5376.157-9QTR115.39124.06106.1677.2310-12QTR115.52124.51104.5077.581-3QTR117.08127.65105.8379.474-6QTR120.11131.87109.4482.127-9QTR119.88129.78110.0881.39(Yen)10-12QTR123.26130.02113.6683.751-3YTD112.61120.19109.0278.721-6YTD112.07119.27108.2877.421-9YTD1-12Full-year1-3YTD113.14120.80107.5777.36113.72121.69106.8077.41117.08127.65105.8379.471-6YTD118.60129.76107.6380.801-9YTD119.03129.77108.4581.001-12120.10129.83109.7581.69Full-yearFull-yearAssumptionFY20221-12122.00130.00112.0084.00Actual*FY2020Actual*FY2020ActualFY2020Actual*FY2021Actual*FY2021ActualFY202131 Mar.30 Jun.30 Sep.31 Dec.31 Mar.30 Jun.30 Sep.31 Dec.112.49119.13107.8375.73113.07120.93107.5777.18114.92124.08105.6677.19117.10126.89103.1977.98117.14129.30110.3781.87120.02131.48110.5282.15119.76129.85111.9782.27125.95130.31115.0785.09Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　1Reconciliation of IFRS results to Core resultsFY20201-12Intangibleassets(Billions of yen)FY20211-12IntangibleassetsIFRS resultsOthersCore results IFRS resultsOthersCore results786.9633.3153.6(273.5)513.5(212.3)(72.6)(117.9)(21.8)301.2(0.1)(1.5)(1.5)298.2(83.5)214.7214.7—-1.21.20.7-0.7-1.9—1.9(0.6)1.31.4——4.81.13.60.14.8—4.8(1.4)3.43.4-786.9633.3153.6(272.3)514.7(206.7)(71.5)(113.5)(21.7)307.9(0.1)(1.5)(1.5)304.9(85.5)219.4219.4-999.8802.8196.9(338.1)661.6(239.7)(76.6)(137.3)(25.8)421.9(0.0)0.1(2.5)419.4(116.4)303.0303.0– – – 2.72.74.1- 4.1- 6.7- – – 6.7(2.0)4.74.7- – – – – – 5.50.83.51.25.5- – – 5.5(1.6)3.83.8- 999.8802.8196.9(335.5)664.3(230.2)(75.8)(129.8)(24.6)434.1(0.0)0.1(2.5)431.6(120.1)311.5311.5- RevenuesSalesRoyalties and other operating incomeCost of salesGross profitOperating expensesMarketing and distributionResearch and developmentGeneral and administrationOperating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interestsCore results Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjustingnon-recurring items recognized by Chugai to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results areused by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as thebasis for payment-by-results.The table above shows the reconciliation of IFRS results into Core results. The detail is as below.Amortization （1.3 billion yen in 2020 and 2.2 billion yen in 2021)Impairment （0.6 billion yen in 2020 and 4.5 billion in 2021）Intangible assetsOthersRestructuring expenses etc. （4.7 billion yen in 2020 and 5.5 billion yen in 2021）Environmental costs （0.1 billion yen in 2020 and none in 2021）Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　2IFRS results (QTR)RevenuesSales　Domestic　OverseasCost of salesGross profitOperating expensesRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeMarketing and distribution Research and development General and administration Operating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interestsEarnings per shareBasic (yen)Diluted (yen)(% of Sales)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)3564ActualFY2020ActualFY2021(Billions of yen)1-3QTR4-6QTR7-9QTR10-12QTR1-3QTRChange(%)4-6QTRChange(%)7-9QTRChange(%)10-12QTRChange(%)179.4144.5101.942.634.926.48.5(61.3)42.4118.265.9(45.7)25.5(15.8)8.8(26.1)14.5(3.9)2.272.440.4(0.0)(0.6)(0.5)71.239.7(19.7)51.528.751.5-31.3731.33188.7161.1102.758.427.627.10.5(70.6)43.8118.162.6(49.9)26.4(17.0)9.0(28.8)15.3(4.1)2.268.236.1(0.0)0.5(0.3)68.436.2(17.6)50.826.950.8-30.8930.85208.4159.198.660.649.335.613.6(69.4)43.6139.066.7(52.4)25.1(17.0)8.2(30.1)14.4(5.2)2.586.741.6(0.0)(0.8)(0.3)85.641.1(25.4)60.128.860.1-36.5836.55210.4168.5105.962.641.940.51.4(72.3)42.9138.265.7(64.2)30.5(22.8)10.8(32.8)15.6(8.6)4.173.935.1(0.0)(0.5)(0.4)73.134.7(20.7)52.324.952.3-31.8231.80168.8130.394.935.438.636.62.0(55.3)42.4113.567.2(49.5)29.3(15.9)9.4(29.7)17.6(3.9)2.364.037.9(0.0)0.3-64.238.0(16.8)47.428.147.4-(5.9)(9.8)(6.9)(16.9)+10.6+38.6(76.5)(9.8)(4.0)+8.3+0.6+13.80.0(11.6)0.0(9.8)(14.7)(8.0)————221.4173.9108.565.347.546.70.8(68.1)39.2153.469.3(56.6)25.6(17.9)8.1(33.6)15.2(5.2)2.396.743.7(0.0)0.3(0.0)97.043.8(26.3)70.731.970.7-+17.3+7.9+5.6+11.8+72.1+72.3+60.0(3.5)+29.9+13.4+5.3+16.7+26.8+41.8———-0.0(40.0)(100.0)+41.8+49.4+39.2287.3234.5159.275.352.752.10.6(104.2)44.4183.163.7(60.9)21.2(18.5)6.4(36.2)12.6(6.3)2.2122.242.5(0.0)0.3+37.9+47.4+61.5+24.3+6.9+46.3(95.6)+50.1+31.7+16.2+8.8+20.3+21.2+40.9——-0.0-(2.8) +833.3119.7+39.841.7(33.7)86.029.9+32.7+43.1–(8.0)+39.286.0-+43.1-98.8-28.8428.82(8.1)(8.0) 43.0242.99+39.3+39.4 52.3152.28+43.0+43.0 60.1160.08+27.96.4 +357.1+53.0322.3264.1156.3107.858.151.8(110.6)41.9211.765.7(72.6)22.5(24.3)7.5(37.8)11.7(10.5)3.3139.143.2(0.0)(0.9)0.3138.442.9(39.6)98.830.7+53.2+56.7+47.6+72.2+38.7+53.2+13.1+6.6+15.2+22.1+88.20.0+80.0+89.3+91.3+88.9———–+88.9+88.9+88.9Other financial income (expense) includes net amount of FX related gains/losses. Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”) implemented a three-for-one stock split of its common stock.“Earnings per share (Basic)” and “Earnings per share (Diluted)” presents the amount after the stock split.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　323ActualFY2020ActualFY20191-12YTD1-3YTD1-6YTD1-9YTD1-12YTD1-3YTDChange(%)1-6YTDChange(%)1-9YTDChange(%)1-12YTDChange(%)(Billions of yen)ActualFY2021IFRS results (YTD)RevenuesSales　Domestic　OverseasCost of salesGross profitOperating expensesRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeMarketing and distribution Research and development General and administration Operating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interestsEarnings per shareBasic (yen)Diluted (yen)(% of Sales)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)686.2588.9437.6151.397.376.520.8(266.1)45.2420.161.2(209.5)30.5(77.2)11.3(107.9)15.7(24.4)3.6210.630.7(0.1)0.5(3.1)207.930.3(50.3)157.623.0157.6- 179.4144.5101.942.634.926.48.5(61.3)42.4118.265.9(45.7)25.5(15.8)8.8(26.1)14.5(3.9)2.272.440.4(0.0)(0.6)(0.5)71.239.7(19.7)51.528.7368.1305.7204.6101.062.553.59.0(131.8)43.1236.364.2(95.7)26.0(32.8)8.9(54.9)14.9(8.0)2.2140.638.2(0.0)(0.2)(0.9)139.637.9(37.3)102.327.8576.5464.8303.2161.6111.789.122.6(201.2)43.3375.365.1(148.0)25.7(49.8)8.6(85.0)14.7(13.2)2.3227.339.4(0.0)(1.0)(1.1)225.139.0(62.7)162.428.2786.9633.3409.1224.2153.6129.624.1(273.5)43.2513.565.3(212.3)27.0(72.6)9.2(117.9)15.0(21.8)2.8301.238.3(0.1)(1.5)(1.5)298.237.9(83.5)214.727.3168.8130.394.935.438.636.62.0(55.3)42.4113.567.2(49.5)29.3(15.9)9.4(29.7)17.6(3.9)2.364.037.9(0.0)0.3 -64.238.0(16.8)47.428.1(5.9)(9.8)(6.9)(16.9)+10.6+38.6(76.5)(9.8)-(4.0)-+8.3-+0.6-+13.8-0.0-(11.6)-0.0–(9.8)-(14.7)(8.0)-390.2304.1203.4100.786.183.32.8(123.4)40.6266.868.4(106.2)27.2(33.8)8.7(63.3)16.2(9.1)2.3160.741.2(0.0)0.6(0.0)161.341.3(43.1)118.130.3+6.0(0.5)(0.6)(0.3)+37.8+55.7(68.9)(6.4)-+12.9-+11.0-+3.0-+15.3-+13.8-+14.3-0.0-(100.0)+15.5-+15.5+15.4-677.5538.7362.6176.0138.8135.43.4(227.6)42.2449.966.4(167.1)24.7(52.2)7.7(99.5)14.7(15.3)2.3282.841.7(0.0)0.9(2.8)280.941.5(76.8)204.230.1+17.5+15.9+19.6+8.9+24.3+52.0(85.0)+13.1-+19.9-+12.9-+4.8-+17.1-+15.9-+24.4-0.0-+154.5+24.8-+22.5+25.7-999.8802.8518.9283.9196.9187.29.8(338.1)42.1661.666.2(239.7)24.0(76.6)7.7(137.3)13.7(25.8)2.6421.942.2(0.0)0.1(2.5)419.441.9(116.4)303.030.3+27.1+26.8+26.8+26.6+28.2+44.4(59.3)+23.6-+28.8-+12.9-+5.5-+16.5-+18.3-+40.1-(100.0)-+66.7+40.6-+39.4+41.1-+41.1-+41.0+41.151.5- 102.3- 162.4- 214.7- 47.4 -(8.0)-118.1 -+15.4-204.2 -+25.7-303.0 – 95.9595.81 31.3731.33 62.2662.18 98.8498.74 130.66130.5328.8428.82(8.1)(8.0) 71.8671.81+15.4+15.5 124.17124.09+25.6+25.7 184.29184.17Other financial income (expense) includes net amount of FX related gains/losses. Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”) implemented a three-for-one stock split of its common stock.“Earnings per share (Basic)” and “Earnings per share (Diluted)” presents the amount after the stock split.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　4356(Billions of yen)1-3QTR4-6QTR7-9QTR10-12QTR1-3QTRChange(%)4-6QTRChange(%)7-9QTRChange(%)10-12QTRChange(%)Core results (QTR)RevenuesSales　Domestic　OverseasCost of salesGross profitOperating expensesRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeMarketing and distribution Research and development General and administration Operating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interests(% of Sales)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)4ActualFY2020188.7161.1102.758.427.627.10.5(70.3)43.6118.462.7(48.8)25.9(16.8)8.9(27.9)14.8(4.1)2.269.736.9(0.0)0.5(0.3)69.837.0(18.0)51.827.551.8- 31.47208.4159.198.660.649.335.613.6(69.1)43.4139.366.8(51.2)24.6(16.7)8.0(29.3)14.1(5.2)2.588.242.3(0.0)(0.8)(0.3)87.041.7(25.9)61.229.461.2- 37.17179.4144.5101.942.634.926.48.5(61.0)42.2118.566.1(44.4)24.7(15.5)8.6(25.0)13.9(3.9)2.274.141.3(0.0)(0.6)(0.5)72.940.6(20.2)52.729.452.7- 32.04ActualFY2021221.4173.9108.565.347.546.70.8(66.8)38.4154.669.8(54.1)24.4(18.1)8.2(31.1)14.0(4.9)2.2100.545.4(0.0)0.3(0.0)100.845.5(27.4)73.333.1+17.3+7.9+5.6+11.8+72.1+72.3+60.0(5.0)-+30.6-+10.9-+7.7-+11.5-+19.5-+44.2-0.0(40.0)(100.0)+44.4-+52.2+41.5-287.3234.5159.275.352.752.10.6(103.8)44.3183.463.8(58.5)20.4(18.2)6.3(34.3)11.9(6.0)2.1124.943.5(0.0)0.3(2.8)122.542.6(34.5)87.930.6+37.9+47.4+61.5+24.3+6.9+46.3(95.6)+50.2-+31.7-+14.3-+9.0-+17.1-+15.4-+41.6-0.0-+833.3+40.8-+33.2+43.6-210.4168.5105.962.641.940.51.4(72.0)42.7138.565.8(62.4)29.7(22.5)10.7(31.3)14.9(8.6)4.176.136.2(0.0)(0.5)(0.4)75.235.7(21.4)53.825.6168.8130.394.935.438.636.62.0(55.0)42.2113.867.4(48.5)28.7(15.8)9.4(28.7)17.0(3.9)2.365.438.7(0.0)0.3- 65.638.9(17.2)48.428.7(5.9)(9.8)(6.9)(16.9)+10.6+38.6(76.5)(9.8)-(4.0)-+9.2-+1.9-+14.8-0.0-(11.7)-0.0–(10.0)-(14.9)(8.2)-322.3264.1156.3107.858.151.86.4(109.8)41.6212.565.9(69.1)21.4(23.6)7.3(35.7)11.1(9.9)3.1143.444.5(0.0)(0.9)0.3142.744.3(40.9)101.831.6+53.2+56.7+47.6+72.2+38.7+27.9+357.1+52.5-+53.4-+10.7-+4.9-+14.1-+15.1-+88.4-0.0+80.0-+89.8-+91.1+89.2-+89.2-+89.2Core earnings per share (diluted) (yen) 53.8- 32.7148.4- 29.42(8.2)-(8.2)73.3- 44.58+41.5-+41.787.9- 53.45+43.6-+43.8101.8-61.90 Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.Other financial income (expense) includes net amount of FX related gains/losses. Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”) implemented a three-for-one stock split of its common stock.Core EPS presents the amount after the stock split.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　51-3YTD1-6YTD1-9YTD1-12YTD1-3YTDChange(%)1-6YTDChange(%)1-9YTDChange(%)1-12YTDChange(%)Core results (YTD)66666RevenuesSales　Domestic　OverseasCost of salesGross profitOperating expensesRoyalties and other operating income　Royalty and profit-sharing income　Other operating income(% of Sales)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)Marketing and distribution Research and development General and administration Operating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interestsWeighted average number of shares in issueused to calculate diluted earnings per share(Millions of shares)Core earnings per share (diluted) (yen)Core payout ratio (%)Dividend per share (Full year) (yen)Dividend per share (Year end) (yen)Dividend per share (Half year) (yen)ActualFY20191-12YTD686.2588.9437.6151.397.376.520.8(265.1)45.0421.161.4(196.2)28.6(73.5)10.7(102.1)14.9(20.6)3.0224.932.8(0.1)0.5(3.1)222.232.4(54.6)167.624.4167.6- 101.9345.81409248ActualFY2020368.1305.7204.6101.062.553.59.0(131.2)42.9236.964.4(93.2)25.3(32.3)8.8(52.9)14.4(8.0)2.2143.739.0(0.0)(0.2)(0.9)142.738.8(38.2)104.528.4576.5464.8303.2161.6111.789.122.6(200.3)43.1376.265.3(144.3)25.0(49.0)8.5(82.2)14.3(13.1)2.3231.940.2(0.0)(1.0)(1.1)229.739.8(64.1)165.628.7179.4144.5101.942.634.926.48.5(61.0)42.2118.566.1(44.4)24.7(15.5)8.6(25.0)13.9(3.9)2.274.141.3(0.0)(0.6)(0.5)72.940.6(20.2)52.729.4786.9633.3409.1224.2153.6129.624.1(272.3)43.0514.765.4(206.7)26.3(71.5)9.1(113.5)14.4(21.7)2.8307.939.1(0.1)(1.5)(1.5)304.938.7(85.5)219.427.9133.3941.2-3075ActualFY2021390.2304.1203.4100.786.183.32.8(121.9)40.1268.468.8(102.5)26.3(34.0)8.7(59.9)15.4(8.7)2.2165.842.5(0.0)0.6(0.0)166.442.6(44.7)121.731.2+6.0(0.5)(0.6)(0.3)+37.8+55.7(68.9)(7.1)-+13.3-+10.0-+5.3-+13.2-+8.7-+15.4-0.0-(100.0)+16.6-+17.0+16.5-677.5+17.5538.7+15.9362.6+19.6176.0+8.9138.8+24.3135.4+52.03.4(85.0)(225.7)+12.7-41.9451.8+20.1-66.7(161.1)+11.6-23.8(52.2)+6.5-7.7(94.1)+14.5-13.9(14.7)+12.2-2.2290.7+25.4-42.9(0.0)0.00.9-(2.8) +154.5+25.8-+23.6+26.6-288.942.6(79.2)209.731.0168.8130.394.935.438.636.62.0(55.0)42.2113.867.4(48.5)28.7(15.8)9.4(28.7)17.0(3.9)2.365.438.7(0.0)0.3- 65.638.9(17.2)48.428.7(5.9)(9.8)(6.9)(16.9)+10.6+38.6(76.5)(9.8)-(4.0)-+9.2-+1.9-+14.8-0.0-(11.7)-0.0–(10.0)-(14.9)(8.2)-(Billions of yen)Forecast(Feb 3thannounced)FY2022Change(%)1-12YTD1150.01031.5646.3385.2118.5114.04.5(460.0)44.6690.060.0(250.0)21.7 +15.0+28.5+24.6+35.7(39.8)(39.1)(54.1)+37.1-+3.9-+8.6-(149.5)13.0+15.2- 440.038.3+1.4- 312.527.2+0.3-999.8802.8518.9283.9196.9187.29.8(335.5)41.8664.366.4(230.2)23.0(75.8)7.6(129.8)13.0(24.6)2.5434.143.4(0.0)0.1(2.5)431.643.2(120.1)311.531.2+27.1+26.8+26.8+26.6+28.2+44.4(59.3)+23.2-+29.1-+11.4-+6.0-+14.4-+13.4-+41.0-(100.0)-+66.7+41.6-+40.5+42.0-+42.0 40.1 7646 30190.0040.0763838+0.3—-52.7- 104.5- 165.6- 219.4- 48.4-(8.2)-121.7-+16.5-209.7-+26.6-311.5 – +42.0-1,6451,6451,6451,6451,6451,6450.01,6450.01,6450.01,6450.0 32.04 63.51 100.68 29.42(8.2)73.99+16.5127.45+26.6189.35Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.Other financial income (expense) includes net amount of FX related gains/losses. Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”) implemented a three-for-one stock split of its common stock. Core EPS presents the amount after the stock split.Weighted average number of shares in issue used to calculate diluted earnings per share presents the amount after the stock split.The dividend for the fiscal year ended December 31, 2019 and the second quarter of the fiscal year 2020 presents the amount prior to the stock split.The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split.The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　6Statements of revenues (QTR)SalesDomesticOncologyAvastinTecentriqPerjetaAlecensaKadcylaHerceptinPolivyRituxanGazyvaFoundation MedicineOther productsPrimaryRonapreveActemraHemlibraEdirolMirceraEnspryngCellCeptBonvivaOxarolEvrysdiOther productsOverseasHemlibra To RocheActemra To RocheAlecensa To RocheEnspryng To RocheNeutroginOther productsRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeRevenuesDomesticOverseasActualFY2020ActualFY20211-3QTR4-6QTR7-9QTR10-12QTR1-3QTRChange(%)4-6QTRChange(%)7-9QTRChange(%)10-12QTRChange(%)144.5101.955.320.47.88.35.62.14.5-1.91.00.63.146.6-9.57.98.84.2-2.22.11.4-10.542.68.68.224.123.56.25.90.10.12.51.134.926.48.5179.4109.569.9161.1102.758.120.48.88.46.62.54.1-1.81.00.63.844.6-9.78.29.54.3-2.32.11.6-7.058.47.97.536.535.910.710.30.30.32.01.127.627.10.5188.7102.786.0159.198.656.019.78.98.16.42.63.7-1.81.10.83.042.6-9.48.45.94.50.32.22.31.6-8.060.65.14.737.036.513.913.61.11.12.31.149.335.613.6208.4100.6107.8168.5105.962.921.112.08.77.33.13.6-1.81.30.93.143.0-10.79.53.64.61.02.42.41.7-6.962.64.54.236.836.013.613.24.04.02.31.441.940.51.4210.4106.2104.3130.394.957.918.814.17.46.03.22.6-1.21.01.02.636.9-9.28.82.93.41.42.02.01.4-5.835.48.58.017.416.96.05.6–2.21.238.636.62.0168.895.373.6(9.8)(6.9)+4.7(7.8)+80.8(10.8)+7.1+52.4(42.2)-(36.8)0.0+66.7(16.1)(20.8)-(3.2)+11.4(67.0)(19.0)-(9.1)(4.8)0.0-(44.8)(16.9)(1.2)(2.4)(27.8)(28.1)(3.2)(5.1)–(12.0)+9.1+10.6+38.6(76.5)(5.9)(13.0)+5.3173.9108.566.220.416.48.27.14.02.60.91.21.11.23.142.3-11.09.94.73.62.22.22.11.5-5.165.324.724.220.519.715.014.50.90.92.51.747.546.70.8221.4109.0112.4+7.9+5.6+13.90.0+86.4(2.4)+7.6+60.0(36.6)-(33.3)+10.0+100.0(18.4)(5.2)-+13.4+20.7(50.5)(16.3)-(4.3)0.0(6.3)-(27.1)+11.8+212.7+222.7(43.8)(45.1)+40.2+40.8+200.0+200.0+25.0+54.5+72.1+72.3+60.0+17.3+6.1+30.7234.5159.267.020.615.58.17.04.12.32.61.21.11.33.192.342.811.610.69.93.72.62.02.01.60.45.075.328.527.825.624.917.216.70.30.32.11.652.752.10.6287.3159.8127.5+47.4+61.5+19.6+4.6+74.20.0+9.4+57.7(37.8)-(33.3)0.0+62.5+3.3+116.7-+23.4+26.2+67.8(17.8)+766.7(9.1)(13.0)0.0-(37.5)+24.3+458.8+491.5(30.8)(31.8)+23.7+22.8(72.7)(72.7)(8.7)+45.5+6.9+46.3(95.6)+37.9+58.8+18.3+56.7+47.6+11.90.0+34.2(2.3)+2.7+41.9(36.1)-(16.7)(7.7)+77.8(6.5)+99.8-+6.5+29.5+36.1(19.6)+250.0(8.3)(12.5)(5.9)-+10.1264.1156.370.421.116.18.57.54.42.33.31.51.21.62.985.934.611.412.34.93.73.52.22.11.61.97.6107.8+7.5(13.2)(14.4)+72.252.5 +1,066.752.0 +1,138.139.3+6.838.711.811.30.30.32.31.758.151.86.4+357.1(92.5)(92.5)+21.4+38.7+27.90.0322.2158.3164.0+53.1+49.1+57.2From the 1st Quarter of FY2021, sales for Foundation Medicine is included “Oncology”, instead of “Others” until FY2020. Also sales for products included ”Bone and Joint”, “Renal Diseases”, “Others” until FY2020, are included “Primary” from the 1st Quarter of FY2021.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　7Statements of revenues (YTD)SalesDomesticOncologyAvastinTecentriqPerjetaAlecensaKadcylaHerceptinPolivyRituxanGazyvaFoundation MedicineOther productsPrimaryRonapreveActemraHemlibraEdirolMirceraEnspryngCellCeptBonvivaOxarolEvrysdiOther productsOverseasHemlibra To RocheActemra To RocheAlecensa To RocheEnspryng To RocheNeutroginOther productsRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeRevenuesDomesticOverseasActualFY20191-12YTDActualFY20201-3YTD1-6YTD1-9YTD1-12YTD1-3YTDChange(%)1-6YTDChange(%)1-9YTDChange(%)1-12YTDChange(%)ActualFY2021588.9437.6240.995.620.630.723.09.026.7-11.93.60.419.3196.6-41.825.236.722.2-9.39.76.9-44.9151.33.63.388.386.545.344.6–9.94.297.376.520.8686.2444.0242.2144.5101.955.320.47.88.35.62.14.5-1.91.00.63.146.6-9.57.98.84.2-2.22.11.4-10.542.68.68.224.123.56.25.90.10.12.51.134.926.48.5179.4109.569.9305.7204.6113.440.716.616.712.34.68.6-3.72.11.27.091.2-19.116.118.38.5-4.54.23.1-17.5101.016.415.760.659.416.816.20.40.44.52.262.553.59.0368.1212.2155.9464.8303.2169.460.425.524.818.77.112.3-5.53.22.09.9133.8-28.624.624.212.90.36.76.54.7-25.5161.621.520.497.696.030.729.81.61.66.83.4111.789.122.6576.5312.8263.7633.3409.1232.381.537.533.526.010.215.9-7.24.62.813.0176.8-39.334.127.817.51.39.18.96.4-32.4224.226.124.6134.4132.044.343.05.65.69.04.8153.6129.624.1786.9419.0368.0130.394.957.918.814.17.46.03.22.6-1.21.01.02.636.9-9.28.82.93.41.42.02.01.4-5.835.48.58.017.416.96.05.6–2.21.238.636.62.0168.895.373.6(9.8)(6.9)+4.7(7.8)+80.8(10.8)+7.1+52.4(42.2)-(36.8)0.0+66.7(16.1)(20.8)-(3.2)+11.4(67.0)(19.0)-(9.1)(4.8)0.0-(44.8)(16.9)(1.2)(2.4)(27.8)(28.1)(3.2)(5.1)–(12.0)+9.1+10.6+38.6(76.5)(5.9)(13.0)+5.3304.1203.4124.139.230.515.713.17.25.20.92.42.12.25.779.3-20.318.77.67.13.54.14.13.0-11.0100.733.232.237.936.521.120.10.90.94.83.086.183.32.8390.2204.3185.9(0.5)(0.6)+9.4(3.7)+83.7(6.0)+6.5+56.5(39.5)-(35.1)0.0+83.3(18.6)(13.0)-+6.3+16.1(58.5)(16.5)-(8.9)(2.4)(3.2)-(37.1)(0.3)+102.4+105.1(37.5)(38.6)+25.6+24.1+125.0+125.0+6.7+36.4+37.8+55.7(68.9)+6.0(3.7)+19.2+15.9+19.6+12.8(1.0)+80.8(4.0)+7.5+57.7(39.0)-(34.5)0.0+75.0(11.1)+28.3-+11.5+19.1(27.7)538.7362.6191.159.846.123.820.111.27.53.53.63.23.58.8171.642.831.929.317.510.7-+8.9(6.2)(2.1)(37.3)+194.1+187.0(17.1)6.2 +1,966.76.2(7.5)6.14.60.416.0176.061.760.063.561.538.336.91.21.26.84.6138.8135.43.4(85.0)(34.9)(35.9)(25.0)(25.0)+35.3+24.3+52.0+23.8+24.80.0677.5364.1313.4+17.5+16.4+18.8(Billions of yen)Forecast(Feb 3thannounced)FY2022+4.7+3.6+1.9(0.4)(0.3)+24.5+78.4+20.0+24.6+28.5(19.6)(35.3)(15.3)(14.2)+138.2Change(%) 1-12YTD1,031.5646.3260.569.462.033.728.716.08.316.24.15.49.17.5385.8+49.9199.0 +157.141.9(3.0)51.810.810.216.77.47.05.18.827.1385.2186.0182.7144.4141.534.132.04.64.58.87.4118.5114.04.5 +282.6+206.7+200.0(39.8)(54.1)(39.1)(17.7)(33.6)(31.9)(29.2)(11.9)(14.6)(51.6)+19.4+14.8+62.9+40.5+35.7+41.4+63.1+72.2(3.3) 1,150.0649.0501.0+15.0+24.3+4.9+26.8+26.8+12.6(0.7)+65.9(3.9)+6.5+53.9(38.4)-(29.2)(2.2)+82.1(10.8)+45.6-+9.9+22.0(19.8)(17.7)+646.2(7.7)(7.9)(3.1)-(27.2)+26.6+337.5+355.3(23.5)(24.2)+13.1+12.1(73.2)(73.2)+1.1+29.2+28.2+44.4(59.3)+27.1+24.7+29.7802.8518.9261.580.962.232.227.715.79.86.85.14.55.111.6257.477.443.241.622.314.49.78.48.26.22.323.6283.9114.2112.0102.8100.150.148.21.51.59.16.2196.9187.29.8999.8522.3477.4From the 1st Quarter of FY2021, sales for Foundation Medicine is included “Oncology”, instead of “Others” until FY2020. Also sales for products included ”Bone and Joint”, “Renal Diseases”, “Others” until FY2020, are included “Primary” from the 1st Quarter of FY2021.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　8ActualFY2019Dec. 31ActualFY2020Mar. 31Jun. 30Sep. 30Dec. 31Mar. 31139.6168.1(47.7)(22.9)237.2255.69.723.521.0309.8547.0- 129.1203.9333.1(26.1)307.0854.0150.1174.4(51.3)(21.5)251.6277.48.423.824.9334.5586.1- 134.0138.7272.7(4.7)268.0854.1169.2172.0(44.7)8.5305.0275.37.724.024.4331.3636.3- 94.1196.6290.7(21.1)269.6905.9172.6179.6(45.2)(18.4)288.5288.39.023.824.1345.1633.6- 136.1182.7318.8(27.2)291.7925.3195.6183.9(58.3)(21.2)300.0289.28.323.924.6346.0646.0- 166.3212.3378.6(44.6)334.0980.0vs. Mar. 31, 2020 vs. Dec. 31, 2020(57.2)0.816.221.5(18.7)2.2(0.9)2.10.94.3(14.4)- 15.0(50.3)(35.2)52.317.02.6(11.7)10.39.221.829.714.0(1.0)2.20.615.845.5- 47.323.370.712.483.0128.5138.4184.7(42.1)0.3281.3291.47.426.025.5350.3631.6- 181.3162.0343.47.7351.0982.6ActualFY2021Jun. 30180.5199.2(68.7)4.0315.0310.66.325.324.7366.8681.8- 204.1187.1391.2(21.0)370.21,052.1vs. Jun. 30, 2020 vs. Dec. 31, 2020(15.1)15.3(10.4)25.215.021.4(2.0)1.40.120.835.8- 37.8(25.2)12.623.636.272.111.327.2(24.0)(4.5)10.035.3(1.4)1.30.335.545.5- 110.0(9.5)100.50.1100.6146.2Sep. 30223.2201.4(100.7)0.6324.5327.65.624.825.7383.7708.2- 204.1192.5396.6(14.2)382.51,090.6vs. Sep. 30, 2020 vs. Dec. 31, 202027.617.5(42.4)21.824.538.4(2.7)0.91.137.762.2- 37.8(19.8)18.030.448.5110.650.621.8(55.5)19.036.039.3(3.4)1.01.638.674.6- 68.09.877.813.090.8165.3(Billions of yen)Dec. 31281.3208.8(97.2)(22.9)370.1338.813.322.028.4402.4772.6- 204.2267.8472.0(56.5)415.51,188.0vs. Dec. 31, 202085.724.9(38.9)(1.7)70.149.65.0(1.9)3.856.4126.6- 37.955.593.4(11.9)81.5208.0Financial position Trade accounts receivable Inventories Trade accounts payable Other net working capital Net working capital Property, plant and equipment Right-of-use assets Intangible assets Other long-term assets – net Long-term net operating assets Net operating assets Debt Marketable securities Cash and cash equivalents Net cash Other non-operating assets – net Net non-operating assets Total net assets Total net assetsTotal assetsTotal liabilitiesAttributable to1,058.9(204.9)1,045.6(191.5)1,072.1(166.2)1,136.1(210.8)1,235.5(255.5)1,144.6(162.0)99.029.5(90.9)93.51,275.8(223.7)Chugai shareholdersNon-controlling interests854.0- 854.1- 905.9- 925.3- 980.0- 982.6- 128.5- 2.6- 1,052.1- Trade accounts receivable: trade receivable and notes receivable Trade accounts payable: trade payable and notes payable Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc. Other long-term assets-net: long-term prepaid expenses, long-term provisions etc. Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.203.7(57.5)146.2- 40.331.81,353.4(262.7)72.1- 1,090.6- 217.3(51.9)165.3- 117.9(7.2)1,538.7(350.7)110.6- 1,188.0- 303.2(95.2)208.0- Net operating assets (NOA) and Net assets:The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, Net operating assets (NOA)and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) andNet assets of IFRS have been excluded, as the Core results concept only applies to the income statement. Net operating assets (NOA):Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital,long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　9Cash flowsOperating profit – IFRS basis Depreciation and impairment of property, plant and equipment Depreciation and impairment of right-of-use assets Amortization and impairment of intangible assets Other cash adjustment on operating profitOperating profit, net of operating cash adjustments (Increase) decrease in trade accounts receivable (Increase) decrease in inventories Increase (decrease) in trade accounts payable Change in other net working capital etc. Investment in property, plant and equipment Lease liabilities paid Investment in intangible assetsTotal (increase) decrease in net working capital etc.Operating free cash flowsas % of revenuesTreasury activities (interest income/expenses, foreign exchange gains/losses etc.)Settlement for transfer pricing taxationTax paidFree cash flowsDividends paidTransaction in own equity instrumentsPurchase of non-controlling interestsNet effect of currency translation on net cashNet change in net cash1-3YTD1-6YTD1-9YTD1-12YTD1-3YTD1-6YTD1-9YTD1-12YTDActualFY20191-12YTD210.619.06.05.34.3245.211.1(9.0)11.8(7.7)6.2(53.0)(8.9)(8.2)181.426.4%(0.9)(3.1)(34.8)142.6(56.4)0.7(2.3)(0.8)83.9ActualFY2020140.610.52.81.62.0157.6(29.5)3.6(3.0)(32.4)(61.4)(40.6)(4.2)(2.3)49.013.3%2.2(0.9)(41.9)8.4(50.4)0.3- (0.8)(42.4)227.316.14.22.33.1253.0(32.9)6.4(2.5)(27.1)(56.1)(47.3)(6.3)(3.1)140.324.3%3.7(1.1)(66.4)76.4(91.2)0.4- 0.2(14.3)72.45.21.50.91.181.0(10.5)(6.8)3.7(21.2)(34.8)(11.1)(2.1)(1.2)31.817.7%0.6(0.5)(41.0)(9.1)(50.1)0.3- (1.4)(60.4)301.222.35.53.62.9335.5(55.9)3.310.5(22.3)(64.4)(57.0)(8.4)(4.3)201.225.6%2.5(1.5)(66.8)135.4(91.4)0.4- 1.245.564.05.31.30.70.972.257.4(1.0)(16.5)0.340.2(28.9)(2.2)(2.9)78.346.4%(2.5)- (63.3)12.4(49.0)0.2- 1.2(35.2)(Billions of yen)ActualFY2021160.710.52.84.02.7180.715.4(15.6)10.0(22.7)(12.9)(35.4)(4.3)(4.4)123.731.7%0.5(0.0)(64.3)59.9(49.3)0.2- 1.812.6282.815.74.36.03.8312.6(27.2)(18.1)41.9(18.1)(21.5)(58.1)(6.3)(6.9)219.832.4%0.9(2.8)(103.6)114.3(98.3)0.3- 1.818.0421.921.05.910.37.3466.4(85.2)(25.5)38.1(10.5)(83.1)(66.0)(9.0)(6.9)301.430.1%(5.4)(2.5)(104.1)189.4(98.6)0.3- 2.393.4Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds　from the sales of assets and reserve payments.Operating free cash flow (Operating FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,”　which shows the company’s cash generation ability from operating activities.Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt、changes in equity are included.The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent.Free cash flow (FCF):The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of theconsolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results conceptonly applies to the income statement.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　10Key Performance indicatorsTotal indicatorCore return on invested capital (Core ROIC)Return on invested capital (ROIC)Ratio of profit to total assets (ROA)Ratio of equity attributable toChugai shareholdersRatio of equity attributable toChugai shareholders (stock price base)Price book value ratio（PBR)Ratio of net income to equity attributable toChugai shareholders (ROE)Margin indicatorROSCOS ratio（vs. Prod. sales）M&D cost ratioR&D cost ratioG&A cost ratioTurn over indicatorTotal asset turnorverWorking capital turnoverInventory turnoverReceivables turnoverPayables turnoverFixed asset turnoverPP&E turnoverintangible assets turnoverDividend / per stock indicatorDividends per share (Half year) Dividends per share (Year end)Dividends per share (Full year)Core earnings per share (diluted) Core payout ratio (%)Equity per share attributableto Chugai shareholders (BPS)Ratio of dividends to equity attributable toChugai shareholders (DOE)Cashflow indicatorCash conversion cycle（CCC）Net cash turnover periodNumber of employees Investment on property, plant and equipmentDepreciationInvestment on intangible assetsAmortizationtimes%%%%%%%%%%%%%MonthsMonthsMonths%%%YenYenYenYen%Yen%Actual20191-1231.930.115.8 80.6 6.5 19.6 32.845.010.714.93.068.9128.77.62.82.2250.0287.32,968.04892140101.93 45.89.58.35.87,39454.017.86.12.6Units1-12As of Dec. 31 As of Mar. 31 As of Jun. 30 As of Sep. 30 As of Dec. 31 As of Mar. 31 As of Jun. 30 As of Sep. 30 As of Dec. 311-121-31-61-91-31-61-9Forecast (Feb 3thannounced)20221-12As of Dec. 31521.2 654.7 883.9 682.2 732.2 644.8 567.3 498.5 399.1 Actual202017.817.59.6 84.5 10.5 11.6 39.042.98.814.42.228.427.914.8 81.4 8.4 18.3 40.243.18.514.32.334.562.27.83.32.0123.6138.71,548.152.597.78.03.32.0189.1212.02,436.29.59.34.9 81.7 8.0 6.0 41.342.28.613.92.217.131.78.53.12.560.067.3757.7Actual202118.217.79.4 82.5 6.9 11.6 42.540.18.715.42.231.230.415.8 80.6 6.2 19.7 42.941.97.713.92.231.158.89.73.63.3117.6130.11,587.952.3100.18.03.74.0199.5219.72,783.97.57.44.0 85.8 7.5 4.8 38.742.29.417.02.314.226.410.03.22.352.258.2676.632.04 63.51 100.68 29.42 73.99 127.45 519.91 519.90 551.13 562.88 596.16 597.67 639.86 663.31 722.50 MonthsMonthsBillions of yenBillions of yenBillions of yenBillions of yen9.14.67,40027.35.21.10.79.14.77,53638.710.52.11.59.45.07,55967.916.12.52.210.96.17,4907.45.32.90.79.96.07,67932.810.55.42.47.75.37,67455.015.76.93.344.343.121.8 77.2 5.2 28.0 43.441.87.613.02.572.1141.07.44.23.4287.5318.44,360.5304676189.35 40.111.5 8.25.77,66472.021.08.44.038.344.613.0383876190.0040.070.023.037.336.518.7 79.3 9.2 23.4 39.143.09.114.42.868.6131.98.13.72.6257.9288.93,319.07530-133.39 41.29.9 9.25.87,55575.222.03.92.9Core ROIC：Core net operting profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit – income taxes)ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholdersTotal asset turnorver: Revenues / Total asset, CCC：[Trade accounts receivable/Sales＋（Inventories – Trade accounts payable）/Cost of sales]* passed monthsNet cash turnover period：Net cash/Revenue* passed monthsCore ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualizedThe Adjusted figures are used for calculating average NOA for Core ROIC and ROICEffective July 1, 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”) implemented a three-for-one stock split of its common stock.The dividend for the fiscal year ended December 31, 2019 and the second quarter of the fiscal year 2020 presents the amount prior to the stock split.The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split.The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.Core EPS and BPS presents the amount after the stock split.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021(IFRS)　　　11Major capital investments plan(The Company)Fujieda area(Fujieda city, Shizuoka)Chugai Life Science Park Yokohama（Totsuka-ku, Yokohama-city, Kanagawa）Ukima Branch（Kita-ku, Tokyo）Facilities（Location）DescriptionPlanned investmentTotal amountInvestmentto-dateFund raisingmethodStart ofconstruction(Billions of yen)SlatedcompletiondateEnhancement of small and middle molecule APIs19.116.5Self-financingMay 2019October 2022Research and development of pharmaceuticals128.896.4Self-financingJune 2019October 2022Manufacture of antibody APIs for early clinical trials12.10.6Self-financingNovember 2021 September 2023(The Company and Domestic subsidiary(Chugai Pharma Manufacturing Co., Ltd.))Facilities (Location)DescriptionFujieda Plant（Fujieda-city, Shizuoka）Manufacture of APIs to cover late stage clinical developmentand early commercial production of small and mid-sizemolecule drugsPlanned investmentTotal amountInvestmentto-dateFund raisingmethodStart ofconstruction(Billions of yen)Slatedcompletiondate55.515.8Self-financingSeptember 2021 October 2024 Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 12 Development pipeline (as of February 3, 2022) Development code Oncology RG7596 Origin Overseas name (Collaborator) Indication # Additional indication Roche/Seagen Polivy Diffuse large B-cell lymphoma (DLBCL) # RG7446 Roche Tecentriq Non-small cell lung cancer (NSCLC) (adjuvant) # Generic name Product name Dosage form polatuzumab vedotin Polivy Injection atezolizumab Tecentriq Injection Mode of Action Anti-CD79b antibody-drug conjugate Engineered anti-PD-L1 monoclonal antibody Stage (Date) Filed (21/12) Filed (21/07) Phase III Phase III Phase III Phase III Phase III (in combination with RG6058) Phase III (in combination with cabozantinib) Phase III Phase III (in combination with RG435) Phase III (in combination with RG435) Phase III (in combination with RG435) Phase III NSCLC (neoadjuvant) # NSCLC (stage III) # Urothelial carcinoma # Muscle-invasive bladder cancer (adjuvant) # Renal cell carcinoma (adjuvant) # Renal cell carcinoma (2nd Line) # Early breast cancer # Ovarian cancer # Hepatocellular carcinoma (HCC) (adjuvant) # HCC (intermediate stage) # Head and neck carcinoma (adjuvant) # Roche Tecentriq (Takeda) Roche Tecentriq Development code Origin Overseas name (Collaborator) Indication # Additional indication Stage (Date) Generic name Product name Dosage form Mode of Action Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 13 RG435 Roche Avastin HCC (adjuvant) # bevacizumab Avastin Injection Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody RG7440 Roche/Array BioPharma Prostate cancer AKT inhibitor RG6264 AF802 / RG7853 RG6058 Roche Phesgo In-house Alecensa (Roche) Roche Breast cancer (Fixed-dose combination, subcutaneous injection) NSCLC (adjuvant) # trastuzumab/pertuzumab Injection Anti-HER2 humanized monoclonal antibody/ HER2 dimerization inhibitory humanized monoclonal antibody ALK inhibitor Anti-TIGIT human monoclonal antibody Esophageal cancer # Pancreatic adenocarcinoma # HCC (intermediate stage) # Small cell lung cancer (SCLC) # SCLC NSCLC NSCLC (stage III) Esophageal cancer Phase III (in combination with RG6058) Phase I Morpheus platform (in combination with RG1569 or RG6058) Phase III (in combination with RG7446) Phase III (in combination with RG7446) Phase III (in combination with RG7446) Phase III Phase III Phase III Phase III (in combination with RG7446) Phase III (in combination with RG7446) Phase III (in combination with RG7446) Phase III (in combination with RG7446) ipatasertib Oral alectinib Alecensa Oral tiragolumab Injection RG6396 OBP-301 GC33 ERY974 RG7421 Roche/ Blueprint Medicine Gavreto Oncolys BioPharma In-house In-house Roche/Exelixis Cotellic NSCLC HCC HCC Solid tumors Solid tumors Development code Origin Overseas name (Collaborator) Indication # Additional indication Breast cancer (adjuvant) RG6171 Roche Breast cancer SERD (Selective Estrogen Receptor Degrader) Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 14 RG7828 Roche Follicular lymphoma Anti-CD20/CD3 bispecific antibody Esophageal cancer Oncolytic type 5 adenovirus Mode of Action RET inhibitor Anti-Glypican-3 antibody humanized monoclonal Anti-Glypican-3/CD3 bispecific antibody MEK inhibitor Phase I (in combination with RG7446 and RG435) Phase I Stage (Date) Phase III Phase III Phase III Phase III Phase II Phase I Phase I Phase I Phase I Phase I Phase I Generic name Product name Dosage form giredestrant Oral mosunetuzumab Injection pralsetinib Oral Injection codrituzumab Injection Injection cobimetinib Oral cibisatamab Injection glofitamab Injection Injection Oral RG7802 Roche Solid tumors Anti-CEA/CD3 bispecific antibody RG6026 Roche Hematologic tumors Anti-CD20/CD3 bispecific antibody STA551 In-house Solid tumors Anti-CD137 agonistic Switch antibody SPYK04 In-house Solid tumors ‒ Development code Origin Overseas name (Collaborator) Indication # Additional indication RG6194 Roche Solid tumors Generic name Product name Dosage form Mode of Action Anti-HER2/CD3 bispecific antibody Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 15 SOF10/RG6440 Solid tumors Anti-latent TGF-β1 monoclonal antibody In-house (Roche) In-house LUNA18 Solid tumors AMY109 In-house Solid tumors Bone and Joint Diseases In-house NRD101 Autoimmune Diseases RAS inhibitor ‒ Knee osteoarthritis / Shoulder periarthritis Sodium hyaluronate RG7880 Roche Inflammatory bowel disease Phase I Human IL-22 fusion protein Neurology RG7916 SA237 / RG6168 Roche/PTC Therapeutics Evrysdi Spinal muscular atrophy (SMA) In-house Enspryng (Roche) Generalized myasthenia gravis (gMG) # SMN2 splicing modifier pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody RG1450 Roche/MorphoSys Alzheimer’s disease Anti-amyloid-beta human monoclonal antibody RG6042 Huntington’s disease Roche/Ionis Pharmaceuticals Antisense oligonucleotide targeting HTT mRNA RG7906 Roche Schizophrenia Partial TAAR1 agonist Stage (Date) Phase I Phase I Phase I Development discontinued Development discontinued (China) Launched (21/08) Phase III Phase III Phase III Phase II Injection Injection Oral Injection purified sodium hyaluronate Suvenyl Injection efmarodocokin alfa Injection risdiplam Evrysdi Oral satralizumab Enspryng Injection gantenerumab Injection tominersen Injection ralmitaront Development code Origin Overseas name (Collaborator) Indication # Additional indication Generic name Product name Dosage form Mode of Action Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 16 RG7935 Roche/Prothena Parkinson’s disease Anti-α-synuclein monoclonal antibody GYM329 / RG6237 Neuromuscular disease Anti-latent myostatin sweeping antibody RG6100 Roche/AC Immune Alzheimer’s disease Anti-tau humanized monoclonal antibody RG6102 Roche/MorphoSys Alzheimer’s disease Anti-amyloid beta/TfR1 fusion protein Oral prasinezumab Injection Injection semorinemab injection Injection Other diseases RG6413 / RG6412 Roche/Regeneron Pharmaceuticals Prevention of symptomatic COVID-19 # MRA/RG1569 In-house Actemra/RoActemra(EU) COVID-19 pneumonia # ACE910 / RG6013 Acquired hemophilia A # RG7716 Diabetic macular edema casirivimab / imdevimab Ronapreve Injection tocilizumab Actemra Injection emicizumab Hemlibra Injection faricimab Injection SARS-CoV-2 neutralizing antibody cocktail Humanized anti-human IL-6 receptor monoclonal antibody Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody Anti-VEGF/Ang2 bispecific antibody SKY59 / RG6107 crovalimab Injection Anti-C5 recycling antibody Neovascular age related macular degeneration (nAMD) Retinal vein occlusion Paroxysmal nocturnal hemoglobinuria (PNH) Atypical hemolytic uremic syndrome (aHUS) Stage (Date) Phase I Phase I Phase I Phase I Approved (21/11) Approved (22/01) Filed (21/11) (Japan) Filed (21/06) Filed (21/06) Phase III Phase III Phase III In-house (Roche) In-house Hemlibra Roche Vabysmo In-house (Roche) Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 17 NXT007 Development code Origin Overseas name (Collaborator) Indication # Additional indication In-house Hemophilia A AMY109 In-house Endometriosis Generic name Product name Dosage form Mode of Action Anti-coagulation factor IXa/X bispecific antibody ‒ RG7992 Roche Non-alcoholic steatohepatitis Phase l Anti-FGFR1/KLB bispecific antibody Stage (Date) Phase l/II Phase l Development discontinued Development discontinued Injection Injection Injection Oral Oral RNA polymerase inhibitor PTH1 receptor agonist RG6422 Roche/Atea Pharmaceuticals COVID-19 PCO371 In-house Hypoparathyroidism In principle, completion of first dose is regarded as the start of clinical studies in each phase. Changes from the last announcement on October 22, 2021 Phase III (DLBCL) → Filed Phase I (Hematologic tumors) → Phase III (Follicular lymphoma) Phase I (Solid tumors) → Phase III (NSCLC) Phase I (Solid tumors: development discontinued) Bone and joint diseases – NRD101 Phase III (Knee osteoarthritis/Shoulder periarthritis: development discontinued) (China) Oncology – RG7596 – RG7828 – RG6396 – AMY109 Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 18 Other diseases – RG6422 – PCO371 Oncology Other Diseases – RG6413/RG6412 Filed (Prophylaxis and asymptomatic COVID-19) → Approved (Prevention of symptomatic COVID-19) – MRA/RG1569 Phase III (COVID-19 pneumonia) → Approved – ACE910/RG6013 Phase III (Acquired hemophilia A) → Filed – SKY59/RG6107 Phase III (Atypical hemolytic uremic syndrome: development started) Phase III (COVID-19: development discontinued) Phase I (Hypoparathyroidism: development discontinued) R&D Activities For the changes during the FY2021 (January 1 – December 31), please refer to page 4 of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the fiscal year 2021).” Changes from January 1 to February 3, 2022 are as follows: – We decided to discontinue the development of AMY109 for solid tumors in consideration of the results of Phase I study. – We obtained approval for the humanized anti-human IL-6 receptor monoclonal antibody MRA/RG1569 (Product name: Actemra) for the treatment of COVID-19 pneumonia in January 2022. Major Chugai originated developments licensed out to 3rd party excluding Roche Development code Chugai / partner Indication Stage Generic name Product name Dosage form Licensee (granted rights ) Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 19 CKI27 / VS-6766 Ovarian cancer CIM331 Atopic dermatitis NSCLC Prurigo nodularis OWL833 / LY3502970 Type 2 diabetes Obesity Phase II (in combination with defactinib) Oral nemolizumab Injection Filled (20/Q3) Japan Phase III (global) Phase III (global) Phase II/III (Japan) Phase II Phase II Oral Generic name Product name Dosage form Guaranteed Mesenchymal Stem Cell 1 (gMSC1) Verastem (exclusive global license for the manufacturing, development and marketing) Maruho (rights for development and marketing in the skin disease area for the Japanese market) Galderma (exclusive global license for the development and marketing excluding Japan and Taiwan) Galderma (exclusive global license for the development and marketing excluding Japan and Taiwan) Maruho (rights for development and marketing in the skin disease area for the Japanese market) Eli Lilly and Company (worldwide development and commercialization rights) Mode of Action RAF/MEK inhibitor Anti-IL-31 receptor A humanized monoclonal antibody Oral non-peptidic GLP-1 receptor agonist 3rd party granted rights TWO CELLS is conducting clinical studies intended to obtain the initial approval in Japan, and will be responsible for manufacturing and suppling gMSC1. Chugai will be responsible for filing regulatory approval, regulatory response to obtain approval, marketing, and clinical studies after the initial approval. The three global phase III CONTACT studies are ongoing to investigate the combination of Tecentriq and cabozantinib. Within the three studies, domestic development for prostate cancer is led by Takeda Pharmaceutical. Sarepta Therapeutics is currently conducting a global phase III study for RG6356 in patients with DMD. Chugai will be responsible for the regulatory filing and marketing of the therapy in Japan. Mode of Action Regenerative cellular medicine for chondrogenesis in the knee Engineered anti-PD-L1 monoclonal antibody Microdystrophin gene therapy Major sales rights holding projects in which third parties are conducting clinical trials Development code Indication # Additional indication gMSC1 Symptomatic articular cartilage defects or Osteochondritis dissecans in the knee Stage Phase III RG7446 Prostate cancer # Phase III (in combination with cabozantinib) atezolizumab Tecentriq Injection RG6356/SRP-9001 Duchenne muscular dystrophy (DMD) Phase III delandistrogene moxeparvovec Injection Major clinical trials in oncology field Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 20 Treatment Expected Indication Study design Study name Stage Planned filing year NSCLC [1st line] NSCLC [stage III] NSCLC [2nd line] NSCLC (neoadjuvant) NSCLC (adjuvant) SCLC PD-L1 positive: Tecentriq ± RG6058 Tecentriq + RG6058 vs. durvalumab Tecentriq + cabozantinib vs. docetaxel Chemo ± Tecentriq Tecentriq vs. best supportive care Tecentriq + chemo ± Avastin Tecentriq + chemo ± RG6058 SKYSCRAPER-01 Phase III SKYSCRAPER-03 Phase III Phase III CONTACT-01 Phase III IMpower030 IMpower010 Phase III Phase III BEAT-SC SKYSCRAPER-02 Phase III 2023 2024 and beyond 2023 2023 Filed 2023 2022 IMvigor011 Phase III 2024 and beyond Muscle-invasive bladder cancer (adjuvant) Renal cell carcinoma (adjuvant) Renal cell carcinoma [2nd line] Tecentriq RG7446 (Tecentriq) Urothelial carcinoma (UC) Tecentriq ± chemo vs. chemo IMvigor130 Phase III 2022 Early breast cancer Ovarian cancer HCC (adjuvant) Tecentriq cabozantinib ± Tecentriq TNBC (adjuvant): paclitaxel ± Tecentriq TNBC (neoadjuvant): nab-paclitaxel ± Tecentriq carboplatin + paclitaxel + Avastin ± Tecentriq Tecentriq + Avastin vs. active surveillance Phase III IMmotion010 CONTACT-03 Phase III IMpassion030 Phase III IMpassion031 Phase III Phase III IMagyn050 IMbrave050 Phase III 2024 and beyond HCC (intermediate stage) Tecentriq + Avastin + TACE vs. TACE TALENTACE Phase III 2024 and beyond HCC [2nd line] Tecentriq + lenvatinib or sorafenib vs. lenvatinib or sorafenib IMbrave251 Phase III 2024 and beyond Head and neck carcinoma (adjuvant) Tecentriq IMvoke010 Phase III 2022 Esophageal cancer Tecentriq + RG6058 vs. Tecentriq vs. placebo SKYSCRAPER-07 Phase III 2024 and beyond Pancreatic adenocarcinoma [1st line] Tecentriq + Actemra vs. gemcitabine + nab-paclitaxel Tecentriq + RG6058 vs. gemcitabine + nab-paclitaxel Morpheus-PC Phase I Prostate cancer castration-resistant: abiraterone ± RG7440 IPATential150 Phase III 2022 2023 2022 2023 ⁻2023 ⁻DLBCL Rituxan + Chemo ± RG7596 POLARIX Phase III Filed Breast cancer NSCLC (adjuvant) Breast cancer Breast cancer (adjuvant) Follicular lymphoma [2nd line] NSCLC RG6264 (SC) + chemo vs. Herceptin (IV) + Perjeta (IV) + chemo ALK fusion-positive: Alecensa vs. chemo HR positive: RG6171 + palbocicilib ± Letrozole HR positive: RG6171 vs. endocrine therapy RG7828 + lenalidomide vs Rituxan + lenalidomide RG6396 vs. platinum-based chemotherapy ± pembrolizumab Phase III FeDeriCa Phase III ALINA Phase III persevERA Phase III lidERA CELESTIMO Phase III AcceleRET-Lung Phase III 2022 2023 2024 and beyond 2024 and beyond 2024 and beyond 2024 and beyond RG7440 (ipatasertib) RG7596 (polatuzumab vedotin) RG6264 AF802 (Alecensa) RG6171 / SERD RG7828 RG6396 FoundationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of February 3, 2022) Alterations Cancer type Relevant drugs Activated EGFR gene alterations NSCLC afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate, dacomitinib hydrate EGFR exon 20 T790M alterations osimertinib mesilate Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for FY2021 (IFRS) 21 alectinib hydrochloride, crizotinib, ceritinib, brigatinib entrectinib capmatinib hydrochloride hydrate dabrafenib mesilate, trametinib dimethyl sulfoxide ALK fusion genes ROS1 fusion genes MET exon 14 skipping alterations BRAF V600E alterations amplification positive) KRAS/NRAS wild-type Microsatellite instability-high Microsatellite instability-high NTRK1/2/3 fusion gene BRCA1/2 alterations BRCA1/2 alterations FGFR2 fusion genes BRAF V600E and V600K alterations Malignant melanoma dabrafenib mesilate, trametinib dimethyl sulfoxide, vemurafenib, encorafenib, binimetinib ERBB2 copy number alterations (HER2 gene Breast cancer trastuzumab (genetical recombination) cetuximab (genetical recombination), panitumumab (genetical recombination) Colorectal cancer nivolumab (genetical recombination) pembrolizumab (genetical recombination) Tumor mutational burden-high Solid tumors pembrolizumab (genetical recombination) 1 entrectinib, larotrectinib sulfate Ovarian cancer Prostate cancer olaparib olaparib Biliary Tract Cancer pemigatinib 1 Application under review and not yet approved for the drug indication as of February 3, 2022 * Underlined are the companion diagnostic features and relevant drugs currently under application for regulatory approval FoundationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of February 3, 2022) Alterations Cancer type Relevant drugs Activated EGFR gene alterations NSCLC afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate EGFR exon 20 T790M alterations osimertinib mesilate alectinib hydrochloride, crizotinib, ceritinib ALK fusion genes ROS1 fusion genes NTRK1/2/3 fusion gene BRCA1/2 alterations Solid tumors Prostate cancer entrectinib entrectinib olaparib